All Episodes

#134 – ESCMID Global Trials: PETER PEN and ASTARTE

#133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship

#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

#131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines

#130 – Dosing Consult: Amoxicillin

#129 – Game of Spores: Blasto, Histo, Crypto, and Cocci

#128 – IDWeek 2025 Recap

#127 – What’s Pneu in Community-Acquired Pneumonia Part 2

#126 – What’s the Microbiome Gut to Do with It

#125 – The Scariest and Baddest: Burkholderia, Achromobacter, and Elizabethkingia

#124 – Dosing Consult: Cefepime

#123 – Rol del Farmacéutico en los PROA en América Latina

#122 – The Role of The Pharmacist in Antimicrobial Stewardship in Latin America

#121 – Finding BALANCE in Antibiotic Durations: The BALANCE Trial

#120 – What’s Pneu in Community-Acquired Pneumonia

#119 – Dosing Consult: Fluconazole

#118 – Hot Topics: What You May Have Missed in Infectious Diseases 2024-2025 (LIVE from MAD-ID)

#117 – Amnio-Oh-No You Didn’t: Modernizing Antimicrobial Regimens for Intraamniotic Infections

#116 – SNAP Out of It: Rethinking Antistaphylococcal Penicillins for S. Aureus Bacteremia – The SNAP Trial PSSA/MSSA Results

#115 – Silver Lining of Shortages: Blood Culture Best Practices

#114 – Dosing Consult: Amoxicillin/Clavulanate

#113 – Ask ChatGPT: The Role of AI in Healthcare

#112 – Say It Ain't Steno: Stenotrophomonas maltophilia Review

#111 – Dosing Consult: Rifampin Part 2

#110 – A Bone to Pick: Biofilm Busters for Prosthetic Joint Infections

#109 – IDWeek 2024 Recap: Practice Changing Papers and ID Potpourri

#108 – IDWeek 2024 Recap: Late Breaker Abstracts and Stewardship Talks

#107 – Dosing Consult: Valganciclovir

#106 – Stewie Struggles: EHR Edition

#105 – Bringing Positive Vibes Only: Breaking News & Emerging Hypotheses for Gram-Positive Bacterial Infections

#104 – Dosing Consult: Rifampin Part 1

#103 – Dosing Consult: Daptomycin

#102 – Oh, the Places Stewardship Will Go! Best Practices for Outpatient Antibiotic Stewardship and Transitions of Care

#101 – BLING III: Does Continuous Infusion Make the Whole Place Shimmer

#100 – Tackling Tetracyclines: Breakpoints 100th Episode!

#99 – Don’t be CRABby: Acinetobacter baumannii review

#98 – Uncomplicated UTIs: Getting Uncomfortable with Uncertainty

#97 – Hot Topics: What Did You Miss in Infectious Diseases in 2023-2024 (LIVE from MAD-ID)

#96 – The Tortured Stewards & Surgeons Department

#95 – A to Z on R&D: Challenges and Solutions for Sustained Antimicrobial Drug Development

#94 – Lock, Stock, & Sterilize: Strategies to Optimize Antimicrobial Lock Therapy & Prevent/Treat Catheter-Related Bloodstream Infections

#93 – Global, Live Journal Club: Ceftobiprole for Complicated Staphylococcus aureus Bacteremia (ERADICATE Study)

#92 – Antibiotic Alchemy: Metallo-Beta-Lactamases

#91 – Teamwork Makes the Dream Work: Preparation Pearls for Stewardship and Microbiology Lab Accreditation Updates

#90 – IDWeek 2023 Recap: Pipeline Agents and Clinical Trials That May Change Your Practice

#89 – IDWeek 2023 Recap: Late Breaking Clinical Trials

#88 – Dosing Consult: Can we BID farewell to Q8H Metronidazole?

#87 – We Love T Cells: Updates in Cytomegalovirus

#86 – The Robin to Your Batman: Ensuring Adequate Beta-lactamase Inhibitor Exposure to Restore Beta-lactam Activity

#85 – Who You Gonna Call? Mythbusters! Antibiotic Myths for Infectious Diseases Clinicians

#84 – Antimicrobial Stewardship and Disaster Medicine: Perspectives from Ukraine

#83 – Dosing Consult: Sulfamethoxazole/trimethoprim

#82 – ID Literature Year in Review (LIVE from MAD-ID)

#81 – Making the Right Choice Easy: Antimicrobial Stewardship in the Emergency Department

#80 – Weighting on a Miracle: Understanding Unknowns of Dosing Children and Adults with Obesity

#79 – HAP & VAP: Let’s Clear the Air

#78 – New Therapies in HIV: The Long Road to Long-acting Antiretrovirals - Are We There Yet?

#77 – Breakpoints Talks Breakpoints: Non-fermenters

#76 – Breakpoints Talks Breakpoints: Fluoroquinolones

#75 – Breakpoints Talks Breakpoints: Aminoglycosides

#74 – Breakpoints Talks Breakpoints: Piperacillin/tazobactam

#73 – You’re a Breakpoint, Harry: Magical Insights from CLSI and USCAST

#72 – This Isn't Just a Phage: A Discussion on Bacteriophage Therapy

#71 – This is a Potential Breakup Song: Controversies in the Management of Infective Endocarditis

#70 – Stewardship Struggles

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

#67 – Nixing the Nidus: Managing Retained Sources in Prosthetic Joint Infections

#66 – The Swinging PEN-dulum: Evolving Approaches to Cephalosporin Use in Penicillin Allergic Patients

#65 – Into the Unknown: Exploring Fever of Unknown Origin with Febrile Podcast

#64 – Putting the Fun in Fungi: A Fun-guide to New Antifungals

#63 – I Never Metapneumovirus that Required Antibiotics: Prevention & Treatment of Common Respiratory Viruses in Adults

#62 – Novel TheraPOOtics: The Microbiome, C. difficile, and LBPs

#61 – Dosing Consult: Linezolid Therapeutic Drug Monitoring

#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID

#59 – Resistance in Pseudomonas aeruginosa: Pearls and Perils

#58 – We're Gonorrhea-valuate: Updates and Implementation of STI Treatment Guidelines

#57 – Dosing Consult: Ceftriaxone

#56 – Empiric Escalation: Gazing into the Crystal Ball for Multidrug-Resistant Gram-Negatives

#55 – One World: Global Perspectives in Antimicrobial Stewardship

#54 – Connecting with our Colleagues: COVID-19 Treatments in Community Pharmacies

#53 – Abscessus and fortuitum and avium, Oh My!: Updates and Controversies in NTM Management

#52 – A Conversation with the Authors of IDSA Guidance on Treatment of AmpC, CRAB, and Stenotrophomonas

#51 – A Conversation with the Authors of IDSA Guidance on Treatment of ESBL, CRE, and DTR Pseudomonas

#50 – Moving to the Algo-rhythm of IDWeek 2021: Highlights in SoMe and ASP

#49 – A PGY-What Now? A Primer on ID Pharmacy Fellowships

#48 – Aligning Goals: Antibiotics in End of Life Care

#47 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 2

#46 – A Nefarious Orchestra: Gram-Negative Resistance Mechanisms Part 1

#45 – Expectation vs. Reality: An Insider look at the OVERCOME and MERINO-2 trials

#44 – The VaxScene, a review of the COVID-19 vaccine landscape in the US with a focus on equitable distribution and vaccine hesitancy

#43 – Level Up: Implementation of Beta-lactam Therapeutic Drug Monitoring

#42 – The Level is in the Details: Beta-lactam Therapeutic Drug Monitoring

#41 – The Gray Zone: Antimicrobial Stewardship in Immunocompromised Hosts

#40 – Breakpoints Talks Breakpoints: Microbiology Labs and Stewardship

#39 – A Little More on the Littles: What Adults Should Know about ID Pediatrics

#38 – You're KID-ding! Myths in ID Pediatrics

#37 – A Gab about Cab: The Short on Long-Acting Antiretrovirals for HIV

#36 – Monoclonal Antibodies: Gateway Drugs for Future Care Delivery Models

#35 – Oral Beta-Lactams, Are We Serious?

#34 – The New Scoop on Poop: Updates in the Management of C. difficile infections

#33 – A Lung Time Coming: Controversies in Community Acquired Pneumonia

#32 – Unsolicited Advice: An Honest Discussion of Burnout in Stewardship

#31 – “Mind the Gap”: Antimicrobial Stewardship at Transitions of Care

#30 – Is More Better? The Role of Combination Therapy for MRSA

#29 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 2

#28 – What You May Have Missed Due to COVID-19: ID Literature Updates 2020 Part 1

#27 – Expert Updates in Gram Negative Resistance: Q&A Session

#26 – OPAT - The Final Frontier, Part 2

#25 – Remdesivir: Ethical and Practical Considerations for Allocation, Tracking, and More

#24 – OPAT – The Final Frontier, Part 1

#23 – Taking a “BITE” Out of Antibiotic Prescribing: Strategies to Improve Antimicrobial Usage in Dentistry

#22 – Taking a “BITE” Out of Antibiotic Prescribing: The Need for Antimicrobial Stewardship in Dentistry

#21 – Frontline Allies: Emergency Medicine and Critical Care Insights into COVID19

#20 – What is Happening Right Now? COVID-19 Challenges and Silver Linings

#19 – Push and Pull: Combating Antibiotic Resistance from Discovery to Market Reform

#18 – Waking the Sleeping Giant: Engaging Nurses in Antimicrobial Stewardship

#17 – See C. diff: A Discussion on Patient Advocacy

#16 – 5 Ways Hospital Pharmacists Can Be Antibiotics Aware

#15 – CDC Core Elements of Hospital Antibiotic Stewardship Programs: 2019 Update

#14 – Pumpkin-Spiced Lessons: Phages, Posters, and Paul Sax

#13 – Provocative Titles and Pro-Con Debates

#12 – Late Breaker Trials and #WhyIVaccinate

#11 – Practice-changing Publications ft. David van Duin

#10 – So You're an Antimicrobial Steward... Now What?

#9 – Show Me the Data!

#8 – Stewardship is a Team Sport

#7 – Rapid Fire Data from ECCMID 2019

#6 – Tazobactam and Tulips: Hot Topics from ECCMID 2019

#5 – Nerding Out at ECCMID 2019

#4 – How ECCMID 2019 went viral

#3 – Lessons Learned From the Front Line

#2 – Implementing Penicillin Skin Testing

#1 – Mythbusting